The management of PMS/PMDD through ovarian cycle suppression

The Premenstrual Syndromes: PMS and PMDD

Volumn , Issue , 2007, Pages 121-130

  Panay, Nick ^a,b   Studd, John W W ^a,c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c LISTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649609458     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (34)

1. Studd JWW. Premenstrual tension syndrome. Br Med J 1979; 1:410.
2. Studd JWW. Ovariotomy for menstrual madness and premenstrual syndrome - 19th century history and lessons for current practice. Gynecol Endocrinol 2006; 22(8):411-15.
3. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992; 36:257-66.
4. Freeman EW, Kroll R, Rapkin A et al. PMS/PMDD Research Group. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10:561-9.
5. Perlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenonecontaining oral contraceptive formulation. Contraception 2005; 72(6):414-21.
6. Magos AL, Brincat M, Studd JWW. Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. Br Med J (Clin Res Ed) 1986; 292:1629-33.
7. Watson NR, Studd JWW, Savvas M, Garnett T, Baber RJ. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989; 2(8665):730-2.
8. Smith RNJ, Studd JWW, Zamblera D, Holland EF. A randomized comparison over 8 months of 100 _g and 200 _g twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995; 102:475-84.
9. Panay N, Rees M, Zakaria F, Guilford S, Studd JWW. Randomized, prospective, placebo controlled, multicentre study of women with severe PMS, treated with 100 _g transdermal oestradiol. BJOG (in preparation).
10. Scarabin PY, Olger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003; 362:428-32.
11. Magos AL, Brewster E, Singh R et al. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for premenstrual syndrome. Br J Obstet Gynaecol 1986; 93:1290-6.
12. Sturdee DW, Wade-Evans T, Paterson ME, Thom M, Studd JW. Relations between bleeding pattern, endometrial history, and oestrogen treatment in menopausal women. Br Med J 1978; 1(6127):1575-7.
13. Panay N, Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 1997; 3:159-71.
14. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (April 2004). The levonorgestrel- releasing intrauterine system (LNG-IUS) in contraception and reproductive health. J Fam Plann Reprod Health Care 2004; 30(22):99-109.
15. Mansel RE, Wisby J. The effect of gonadotrophin suppression by danazol on symptomatic breast disease. Br J Surg 1980; 67:827.
16. Watts JF, Butt WR, Logan Edwards R. A clinical trial using danazol for the treatment of premenstrual tension. Br J Obstet Gynaecol 1987; 94:30-4.
17. Hahn PM, Van Vugt DA, Reid RL. A randomized, placebocontrolled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 1995; 20(2):193-209.
18. Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O’Brien PM. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. Br J Obstet Gynaecol 2004; 111(6):585-93.
19. Sundstrom I, Nyberg S, Bixo M, Hammarback S, Backstrom T. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand 1999; 78(10):891-9.
20. Leather AT, Studd JWW, Watson NR, Holland EF. The prevention of bone loss in young women treated with GnRH analogues with add back estrogen therapy. Obstet Gynaecol 1993; 81(1):104-7.
21. Di Carlo C, Palomba S, Tommaselli GA et al. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril 2001; 75:380-4.
22. Sagsveen M, Farmer J, Prentice A, Breeze A. Gonadotrophinreleasing analogues for endometriosis: bone mineral density. Cochrane Datbase Syst Rev 2003; (4):CD001297.
23. Magill PJ, Progesterone Study Group. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. Br J Gen Pract 1995; 45:589-93.
24. Wyatt K, Dimmock P, Jones P, Obhrai M, O’Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. Br Med J 2001; 323:1-8.
25. Dalley A. Women Under the Knife. London: Huchinson Radius; 1991.
26. Battey R. The history of Battey’s operation. Atlanta Med Surg J 1886; 3:657-75.
27. Casson P, Hahn PM, Van Hugt DA, Reid RL. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 1990; 162(1):99-105.
28. Casper RF, Hearn MT. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 1990; 162(1):105-9.
29. Cronje WH, Vashisht A, Studd JW. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 2004; 19(9):2152-5.
30. Studd JWW. Prophylactic oophorectomy. Br J Obstet Gynaecol 1989; 96:506-9.
31. Panay N, Studd JWW. The psychotherapeutic effects of estrogens. Gynecol Endocrinol 1998; 5:353-65.
32. Studd JWW, Panay N. Hormones and depression in women. Climacteric 2004; 7:338-46.
33. Huo L, Straub RE, Schmidt PJ et al. Risk for premenstrual dysphoric disorder with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry 2007; June; [Epub ahead of print].
34. Panay N. The Management of Premenstrual Syndrome Green Top Guidelines. RCOG Press 2007 (submitted).